The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
|Articles|January 12, 2022
Daily OTC Pearl: Histaminum
Author(s)Saro Arakelians, PharmD
Histaminum is for allergies caused by pollen, ragweed, mold, dust mites, and pet dander.
Advertisement
OTC/Lifestyle Pearl of the Day: Histaminum
Indication: Histaminum is a homeopathic medication for allergy relief.
Insight:
- Active ingredient: Histaminum hydrochloricum 30C HPUS (0.443 mg)
- Inactive ingredients: lactose, sucrose.
- Treats allergies caused by pollen, ragweed, mold, dust mites, and pet dander.
- Directions to use: Foradults and children, at the onset of symptoms dissolve 5 pellets under the tongue every 15 minutes for 1 hour. Then, dissolve 5 pellets under the tongue 3 times a day until symptoms are relieved or as directed by a physician.
- If pregnant or breastfeeding, ask a provider before using the product.
Sources:
Advertisement
Related to this article
Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.
The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
3
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
4
Mavacamten Benefit Holds at 56 Weeks in Adolescents With oHCM
5